Not sure what to make of the CR.
EBITDA to 30/6 $5.9
1:3 share offer fully underwritten by staff and mates will add close to 89m shares to the existing 265m (total about 354 M)
$ value about $3.9 mill
Thinking they will have Debt ($8m) covered or have around $17m for acquisitions.
Is it a war chest for tight times, or part of a more aggressive strategy.
If shares stay around .05c expect market cap to be around $18m come 1/7/20.
Does anybody have a formula for calculating market cap of a startup, in the mining services industry, with debt covered, with assets in excess of 20M, no value against goodwill, in uncertain times, with a possible future EBITDA equal to or around $5 ( Is this a reasonable forecast for 12 months given that the last 9 month have produced $5.9m and we face very uncertain times) I will add to the existing long held holding with this offer.
- Forums
- ASX - By Stock
- News: VYS Vysarn Expects Full Year EBITDA To 30 June Will Be About $5.90M
Not sure what to make of the CR. EBITDA to 30/6 $5.9 1:3 share...
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add VYS (ASX) to my watchlist
|
|||||
Last
32.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $133.9M |
Open | High | Low | Value | Volume |
32.0¢ | 32.5¢ | 32.0¢ | $28.93K | 90.35K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 1290 | 32.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
32.5¢ | 48739 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 21261 | 0.315 |
5 | 184000 | 0.310 |
2 | 13114 | 0.305 |
1 | 35000 | 0.300 |
2 | 107389 | 0.290 |
Price($) | Vol. | No. |
---|---|---|
0.325 | 48739 | 1 |
0.330 | 100000 | 1 |
0.335 | 13548 | 1 |
0.340 | 122239 | 6 |
0.345 | 100000 | 1 |
Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
Featured News
RNU
Renascor wins a funding boost given it wants to produce a critical mineral – but $5M award pales in comparison to some
TLX
Telix jumps 11.6% as US government indicates proposed medicare changes won't affect prostate cancer drug
VYS (ASX) Chart |